1. BTC1.04 Genomic profiling of IDH-wildtype and IDH-mutant initial and matched recurrent glioblastomas reveals clinically actionable mutations (e.g. BRCA1/2) and resistance signatures. (19th September 2018) Authors: McInerney, C E; Ellis, H P; Schrimpf, D; Sahm, F; Stupnikov, A; Wadsley, M; Wragg, C; White, P; Prise, K M; McArt, D G; Kurian, K M Journal: Neuro-oncology Issue: Volume 20(2018)Supplement 3 Page Start: iii215 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. BTC1.04 Genomic profiling of IDH-wildtype and IDH-mutant initial and matched recurrent glioblastomas reveals clinically actionable mutations (e.g. BRCA1/2) and resistance signatures. (19th September 2018) Authors: McInerney, C E; Ellis, H P; Schrimpf, D; Sahm, F; Stupnikov, A; Wadsley, M; Wragg, C; White, P; Prise, K M; McArt, D G; Kurian, K M Journal: Neuro-oncology Issue: Volume 20(2018)Supplement 3 Page Start: iii215 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. C.07 Predicting individualized risk of recurrence: development and validation of a DNA-methylation based nomogram in meningioma. (5th June 2019) Authors: Nassiri, F; Mamatjan, Y; Suppiah, S; Badhiwala, J; Mansouri, S; Karimi, S; Saarela, O; Poisson, L; Ng, H; Noushmehr, H; Harter, P; Baumgarten, P; Weller, M; Preusser, M; Mende, C; Sahm, F; von Deimling, A; Aldape, K; Zadeh, G Journal: Canadian journal of neurological sciences Issue: Volume 46(2019)Supplement 1 Page Start: S13 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. C.07 Predicting individualized risk of recurrence: development and validation of a DNA-methylation based nomogram in meningioma. (June 2019) Authors: Nassiri, F; Mamatjan, Y; Suppiah, S; Badhiwala, J; Mansouri, S; Karimi, S; Saarela, O; Poisson, L; Ng, H; Noushmehr, H; Harter, P; Baumgarten, P; Weller, M; Preusser, M; Mende, C; Sahm, F; von Deimling, A; Aldape, K; Zadeh, G Journal: Canadian journal of neurological sciences Issue: Volume 46(2019)Supplement 1 Page Start: S13 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. JS08.6.A A connectivity signature for glioblastoma. (5th September 2022) Authors: Hoffmann, D C; Hai, L; Wagener, R; Mandelbaum, H; Xie, R; Hausmann, D; Dominguez Azorín, D; Weil, S; Sievers, P; Cebulla, G; Ito, J; Warnken, U; Venkataramani, V; Ernst, K; Reibold, D; Will, R; Suvà, M L; Herold-Mende, C; Sahm, F; Winkler, F Journal: Neuro-oncology Issue: Volume 24(2022)Supplement 2 Page Start: ii8 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. KS01.3.A Tumoral MHC class II expression in gliomas drives T cell exhaustion. (9th September 2021) Authors: Chih, Y; Sahm, K; Sadik, A; Bunse, T; Trautwein, N; Pusch, S; Stevanovic, S; Opitz, C; Deimling, A; Wick, W; Sahm, F; Bunse, L; Platten, M Journal: Neuro-oncology Issue: Volume 23: Supplement 2 (2021) Page Start: ii3 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. KS05.6.A Oral DNA vaccination targeting VEGFR2 combined with the anti-PD-L1 antibody avelumab in patients with progressive glioblastoma - final results. NCT03750071. (5th September 2022) Authors: Wick, W; Wick, A; Chinot, O; Sahm, F; von Deimling, A; Jungk, C; Mansour, M; Podola, L; Lubenau, H; Platten, M Journal: Neuro-oncology Issue: Volume 24(2022)Supplement 2 Page Start: ii6 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. OS11.5.A PATZ1 fusions define a novel molecularly distinct CNS tumor entity with a broad histological spectrum. (9th September 2021) Authors: Al Halabi, K T; Sievers, P; Stichel, D; Sommerkamp, A C; Sill, M; Jäger, N; Wittmann, A; Kramm, C; Snuderl, M; Pfister, S M; von Deimling, A; Sahm, F; Jones, D T W Journal: Neuro-oncology Issue: Volume 23: Supplement 2 (2021) Page Start: ii14 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. OS12.4.A MHC class II-restricted transgenic T cell receptor therapy targeting mutant capicua transcriptional repressor in experimental gliomas. (9th September 2021) Authors: Kilian, M; Friedrich, M; Sanghvi, K; Green, E; Pusch, S; von Deimling, A; Wick, W; Sahm, F; Platten, M; Bunse, L Journal: Neuro-oncology Issue: Volume 23: Supplement 2 (2021) Page Start: ii15 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. OS12.7.A Characterization of intra-tumoral heterogeneity and differential immune activation during malignant progression of meningiomas on single cell level. (9th September 2021) Authors: Blume, C; Dogan, H; Schweizer, L; Wick, W; Weller, M; Mann, M; Kalamarides, M; von Deimling, A; Schlesner, M; Sahm, F Journal: Neuro-oncology Issue: Volume 23: Supplement 2 (2021) Page Start: ii15 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗